Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,341
  • Shares Outstanding, K 27,919
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,340 K
  • 60-Month Beta -0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RVPH with:

Options Overview Details

View History
  • Implied Volatility 131.74% ( -18.76%)
  • Historical Volatility 96.40%
  • IV Percentile 65%
  • IV Rank 23.80%
  • IV High 451.69% on 10/18/23
  • IV Low 31.82% on 02/26/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 192
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 12,835
  • Open Int (30-Day) 12,076

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +13.11%
on 03/22/24
4.07 -25.80%
on 03/26/24
-0.06 (-1.95%)
since 03/18/24
3-Month
2.67 +13.11%
on 03/22/24
4.83 -37.47%
on 02/13/24
-1.05 (-25.80%)
since 01/18/24
52-Week
2.67 +13.11%
on 03/22/24
9.25 -67.35%
on 05/04/23
-1.91 (-38.74%)
since 04/18/23

Most Recent Stories

More News
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals...

RVPH : 3.02 (-5.63%)
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of...

RVPH : 3.02 (-5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment...

See More

Key Turning Points

3rd Resistance Point 3.37
2nd Resistance Point 3.29
1st Resistance Point 3.15
Last Price 3.02
1st Support Level 2.93
2nd Support Level 2.85
3rd Support Level 2.71

See More

52-Week High 9.25
Fibonacci 61.8% 6.74
Fibonacci 50% 5.96
Fibonacci 38.2% 5.18
Last Price 3.02
52-Week Low 2.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar